BioSpace News Archive

Since the CRISPR genome editing technology was invented in 2012, it has shown great promise to treat a number of intractable diseases.

From jeans to orange juice to laundry detergent: None would be possible without the activity of enzymes. Currently, enzymes used in industry are produced through an expensive, laborious fermentation process, requiring cold storage.

The Board of the Californian Prostitutes Education Project (CALPEP) announces that Jamila Shipp has been appointed Executive Director of the agency.

MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today announced that Tassos Gianakakos, Chief Executive Officer, will present at the 37th Annual J.P. Morgan Healthcare Conference on Monday, January 7th, 2019, at 8:30 a.m. PT (11:30 a.m. ET) in San Francisco.

MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced the appointment of William C. Fairey as Chief Commercial Officer and Executive Vice President.

MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of serious cardiovascular diseases, today reported financial results for the fourth quarter and full year ended December 31, 2018.

The MagMAX Microbiome Ultra Nucleic Acid Isolation Kit is a new high-throughput sample processing tool used to advance microbiome research.